Sophiris Bio, Inc.
(NASDAQ : SPHS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.29%300.261.4%$596.56m
AMGNAmgen, Inc.
0.15%233.771.3%$511.86m
GILDGilead Sciences, Inc.
1.74%67.081.0%$364.16m
REGNRegeneron Pharmaceuticals, Inc.
1.06%372.262.6%$296.10m
VRTXVertex Pharmaceuticals, Inc.
0.08%223.251.9%$267.50m
ILMNIllumina, Inc.
2.08%326.473.5%$239.80m
ALXNAlexion Pharmaceuticals, Inc.
6.02%113.892.0%$195.68m
ARWRArrowhead Pharmaceuticals, Inc.
2.66%67.2712.0%$195.66m
EXASEXACT Sciences Corp.
3.15%86.2424.0%$182.79m
CLVSClovis Oncology, Inc.
8.47%9.6114.7%$181.81m
SRPTSarepta Therapeutics, Inc.
-0.46%109.4614.6%$145.45m
AAgilent Technologies, Inc.
0.88%82.251.6%$143.48m
NBIXNeurocrine Biosciences, Inc.
0.28%116.815.0%$128.05m
BMRNBioMarin Pharmaceutical, Inc.
-0.20%79.924.3%$126.79m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$126.10m

Company Profile

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.